All In Biotech

Drug Trial Radar · NCT02099058

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

237

Actual

Start

Jan 15, 2014

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

Conditions

  • Advanced Solid Tumors Cancer

Interventions

  • OsimertinibDrug

    It is administered orally everyday.

  • NivolumabDrug

    It is an intravenous infusion administered every 14 days.

  • Telisotuzumab vedotinDrug

    It is administered by infusion in 21-day dosing cycles.

  • Telisotuzumab vedotinDrug

    It is administered by infusion in 28-day dosing cycles.

  • ErlotinibDrug

    It is administered orally everyday.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Up to 24 Months
  2. Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or NivolumabTime frame: Up to 24 Months
  3. Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)Time frame: Up to 24 months
  4. Maximum observed plasma concentration (Cmax)Time frame: Up to 24 months
  5. Time to Cmax (Tmax)Time frame: Up to 24 months
  6. Terminal elimination half lifeTime frame: Up to 24 months

Locations

36 sites in 9 countries. Site status is shown where the registry gives one.

  • Scottsdale Healthcare /ID# 123761

    Scottsdale, Arizona

  • City of Hope /ID# 153759

    Duarte, California

  • University of California, Los Angeles /ID# 148295

    Los Angeles, California

  • UC Irvine /ID# 165107

    Orange, California

  • University of California, Davis Comprehensive Cancer Center /ID# 129805

    Sacramento, California

  • Univ of Colorado Cancer Center /ID# 123759

    Aurora, Colorado

  • The University of Chicago Medical Center /ID# 136995

    Chicago, Illinois

  • Ingalls Memorial Hosp /ID# 165876

    Harvey, Illinois

  • Massachusetts General Hospital /ID# 129804

    Boston, Massachusetts

  • Dana-Farber Cancer Institute /ID# 168782

    Boston, Massachusetts

  • Duplicate_Henry Ford Health System /ID# 149857

    Detroit, Michigan

  • Herbert Herman Cancer Center /ID# 149858

    Lansing, Michigan

  • Washington University-School of Medicine /ID# 143798

    St Louis, Missouri

  • Summit Medical Group-Florham Park /ID# 217651

    Florham Park, New Jersey

  • Northwell Health - Monter Cancer Center /ID# 218170

    Lake Success, New York

  • Montefiore Medical Park at Eastchester /ID# 218445

    The Bronx, New York

  • Duke Cancer Center /ID# 123763

    Durham, North Carolina

  • Tennessee Oncology, PLLC /ID# 129802

    Nashville, Tennessee

  • Mary Crowley Cancer Research /ID# 123760

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center /ID# 154648

    Houston, Texas

  • Virginia Cancer Specialists - Fairfax /ID# 165708

    Fairfax, Virginia

  • Universitair Ziekenhuis Antwerpen /ID# 170118

    Edegem, Antwerpen, Belgium

  • Duplicate_Tampere University Hospital /ID# 165065

    Tampere, Pirkanmaa, Finland

  • AP-HM - Hopital de la Timone /ID# 151570

    Marseille, Bouches-du-Rhone, France

  • Institut Gustave Roussy /ID# 132747

    Villejuif, Val-de-Marne, France

  • Duplicate_Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS /ID# 164077

    Meldola, Emilia-Romagna, Italy

  • National Cancer Center Hospital East /ID# 217570

    Kashiwa-shi, Chiba, Japan

  • National Cancer Center Hospital /ID# 217571

    Chuo-ku, Tokyo, Japan

  • Radboud Universitair Medisch Centrum /ID# 246908

    Nijmegen, Gelderland, Netherlands

  • Yonsei University Health System Severance Hospital /ID# 217333

    Seoul, South Korea

  • Duplicate_The Catholic University of Korea, ST. Vincent's Hospital /ID# 233378

    Suwon, Gyeonggido, South Korea

  • Asan Medical Center /ID# 217334

    Seoul, Seoul Teugbyeolsi, South Korea

  • China Medical University Hospital /ID# 217494

    Taichung, Taichung, Taiwan

  • National Cheng Kung University Hospital /ID# 167175

    Tainan, Tainan, Taiwan

  • Taipei Veterans General Hosp /ID# 217392

    Taipei, Taipei, Taiwan

  • National Taiwan University Hospital /ID# 167173

    Taipei City, Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.